Why Mobile Phlebotomy Companies and Labs Should Be on Alert
Recent fraud case involving phlebotomy company shows why labs need to pay special attention to Medicare specimen collection and travel allowance rules.
Recent fraud case involving phlebotomy company shows why labs need to pay special attention to Medicare specimen collection and travel allowance rules.
A look at the US end-of-emergency game plan and how it will impact lab compliance.
FDA will still be able to issue EUAs for COVID-19 tests after May 11.
Your current COVID-19 testing arrangements may no longer be compliant on May 11.
Recent OIG report suggests some labs might have gamed Medicare coverage rules in 2020 by billing for unusually high numbers of such tests.